Chk2 Inhibitor for Recurrent EpitheliAl periToneal fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Seoul National University Hospital
Updated on 29 January 2021


This study aims to assess the safety and tolerability of PHI-101 in patients with platinum-resistance/refractory ovarian, fallopian tubal, and primary peritoneal cancer. This study also evaluates the pharmacokinetics of PHI-101 and efficacy of PHI-101 during treating platinum-resistance/refractory ovarian, fallopian tubal, and primary peritoneal cancer.

PHI-101 is a CHK2 inhibitor that is a checkpoint kinase binding specifically to CHK2, rather than CHK1, and it inhibits the DDR system by inhibiting the ATM-CHK2 pathway, which is activated in response to DSBs. When a high-grade serous ovarian (HGSO) cancer cell line and various ovarian cancer cell lines (CAOV3, OVCAR3, SK-OV-03, and SW626) were treated with PHI-101 in a non-clinical study, the therapeutic effect of PHI-101 against ovarian cancer was demonstrated by a decrease in viability of ovarian cancer cells. In addition, a stronger growth inhibition effect was observed compared to that of treatment with olaparib or rucaparib alone, and a much stronger inhibition effect was observed when concomitantly used with paclitaxel, cisplatin, and topotecan. Based on the aforementioned results of the non-clinical studies, the potential of PHI-101 as a new treatment or concomitant cytotoxic chemotherapeutics for patients with ovarian cancer who are resistant to existing antineoplastic drugs was confirmed.


In this study, a maximum of 6 dose levels (cohorts) were planned for daily oral administration of PHI-101. Subjects who meet the inclusion/exclusion criteria of this study will be enrolled in each cohort and assessed for safety and tolerability after administering PHI-101 to determine the MTD. Subjects will be enrolled sequentially starting from the low-dose cohort, and DLT will be assessed for the first 28 days (Cycle 1) after the first dose of PHI-101. Before DLT is assessed in a specific cohort, enrolling a subsequent subject in the next higher dose cohort will not be allowed.

According to the accelerated 3+3 design, the accelerated dose escalation scheme, which assesses DLT in 1 subject in each cohort ('single subject cohort'), is applied until toxicity (ADRs) related to PHI-101 [CTCAE version 5.0] grade 2 occurs. If ADRs grade 2 do not occur in 1 subject, DLT can be assessed in one level higher cohort according to the SRC's recommendation. If an ADR grade 2 occurs in a specific cohort, the accelerated 3+3 design will be immediately switched to the standard 3+3 scheme, and 2 additional subjects will be enrolled in that cohort (1 subject + 2 additional subjects) to assess DLT during 1 cycle.

After switching to the standard 3+3 scheme, 3 to 6 subjects will be enrolled in each cohort. If no DLT is observed in the first 3 subjects, DLT can be assessed in one level higher cohort according to the SRC's recommendation. If DLT is observed in 1 out of 3 subjects (DLT: 1/3 subject), that cohort will be expanded to 6 subjects by enrolling 3 additional subjects. If 2 out of 3 to 6 subjects experience DLT (DLT: 2/3 to 6 subjects), this means that the MTD is exceeded. Thus, additional enrollment will be ended for that cohort. The one level lower cohort will expand to 6 subjects (If 6 subjects were already enrolled in that cohort, additional enrollment is unnecessary).

A subject not evaluable for DLT (withdrawal for reasons other than AEs or ADRs, or less than 20 out of 28 doses of PHI-101 were administered during Cycle 1) may be replaced by another subject according to the judgment of the investigator (decision/recommendation of the SRC, if necessary). If a subject in the single subject cohort is not evaluable for DLT, a substitute will be enrolled in the same cohort (1 subject + 1 additional subject) to assess DLT. If it is determined not to replace the subject not evaluable for DLT, the subject will be considered to have experienced DLT when the dose escalation is decided.

If DLT is observed in > 1 out of 6 subjects in a specific cohort () and DLT is observed in 1 out of 6 subjects in the cohort (-1) that is one level lower than the specific cohort, the one level lower cohort (-1) will be considered as the MTD. The dose of PHI-101 will be escalated until an MTD is determined. If the MTD is not determined at the MPD, dose escalation will be ended at that dose (Addition of cohorts may be reviewed by and discussed with the SRC, if necessary, but reporting to the MFDS and the IRB and protocol amendment should occur first.) According to the schedule of activities (SOA), observation, questioning, examination, and tests to assess the safety and tolerability of PHI-101, PK sampling to assess PK, and tumor response assessment to explore efficacy will be performed.

After the EOT of PHI-101, the EOT visit will take place. Survival of subjects and initiation of new antineoplastic therapy will be periodically checked until the EOS. The follow-up will be performed for 1 year after the EOS to obtain such information.

Condition Platinum Resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
Treatment PHI-101 administration
Clinical Study IdentifierNCT04678102
SponsorSeoul National University Hospital
Last Modified on29 January 2021


Yes No Not Sure

Inclusion Criteria

Females aged 19 years at the time of informed consent
Pregnancy (childbearing potential and planning a pregnancy) and breast-feeding status Women of non-childbearing potential, women who are not pregnant or breast-feeding, or women who are not planning a pregnancy during the study
Women of childbearing potential (Section [](telnet:// who
have a confirmed negative pregnancy test at screening and immediately before
administration of PHI-101 and agree to use an effective contraceptive
method(s) (Section [](telnet:// required in this protocol
for 6 months (24 weeks) from the last dose of PHI-101
\. Indication
Histologically or cytologically confirmed ovarian cancer, fallopian tube
carcinoma, or primary peritoneal cancer
Epithelial malignant tumors diagnosed through local histopathological findings
[WHO Histological Classification, 2014]
except LGSC, mucinous carcinoma of the ovary, MMMT, and LAP, which are
classified as LCOH, [NCCN Guideline version 2.2019]
LAP = low malignant potential (ovarian borderline epithelial tumor); LCOH =
less common ovarian histopathology; LGSC = low-grade serous carcinoma; MMMT =
malignant mixed Mullerian tumor (carcinosarcoma); NCCN Guideline = National
Comprehensive Cancer Network Guideline; WHO Histological Classification =
World Health Organization Histological Classification Platinum-refractory
cancer or platinum-resistance cancer
Disease progression during platinum-based antineoplastic therapy, Disease progression within 6 months (24 weeks) from completion of platinum-based antineoplastic therapy Inoperable subjects who are refractory to, cannot receive, or refuse standard of care, which is currently known to be clinically beneficial Subjects with 1 measurable lesion or nonmeasurable, but evaluable lesion that meets [RECIST version 1.1] RECIST = Response Evaluation Criteria in Solid Tumors 4. Expected life expectancy 12 weeks 5. [ECOG PS] 1 ECOG PS = Eastern Cooperative Oncology Group Performance Status 6. Subjects who have adequate hepatic, renal, and hematological function confirmed by the following laboratory tests (a re-test will be allowed during the screening period) ANC 1,500/mm3 (without administration of G-CSF within 2 weeks prior to baseline) Hb 10.0 g/dL (without transfusion within 2 weeks prior to baseline) Platelet count 75,000/mm3 (without transfusion within 2 weeks prior to baseline) Total bilirubin 1.5 x ULN AST and ALT 3.0 x ULN ( 5 x ULN for patients with liver metastases or hepatocellular carcinoma) Serum creatinine (or CrCl) Serum creatinine 1.5 x ULN CrCl 60 mL/min (by Cockcroft-Gault equation) 7. Prior antineoplastic therapy and treatment Prior cytotoxic chemotherapy 5 times
Reversible side effects from prior antineoplastic therapy (operation, drug
radiation therapy, etc.) resolved to [CTCAE version 5.0] grade 1 or better
Subjects should not have had major surgery, antineoplastic therapy or experimental therapy, or direct radiation therapy on hematopoietic site within 4 weeks prior to baseline and should not be administered nitrosoureas or mitomycin-C within 6 weeks prior to baseline
CTCAE = Common Terminology Criteria for Adverse Events
\. Subjects who voluntarily decided to participate and provided written
consent after they were given sufficient explanation of this study
\. Subjects who are able to understand the study procedures and restrictions
and willing to comply with them during the study

Exclusion Criteria

) Subjects with known or suspected hypersensitivity or intolerance to the active ingredient or excipients of PHI-101 2) Subjects considered ineligible or unable to participate in this study according to the investigator's judgement for other reasons
Medical history or current medical condition and disease 3) Subjects with the
following cardiac insufficiency or cardiovascular disease (but not limited
Evidence of myocardial ischemia or myocardial infarction within 12 weeks prior to baseline
[NYHA Functional Classification] II NYHA = New York Heart Association LVEF < 50% confirmed by ECHO or MUGA scan LVEF = left ventricular ejection fraction; ECHO = echocardiography; MUGA = Multi-gated acquisition blood pool scintigraphy
Clinically significant cardiac arrhythmia that is uncontrolled by the adequate and optimal treatments
Corrected QT (QTc) interval > 450 msec (for both men and women) or long QT
syndrome (or family history)
QT interval (QTcF) corrected using Fridericia's formula will be used. In case of bundle branch block, the Bazett's formula will be used (QTcB). 4) Subjects with the following gastrointestinal diseases that affect intake or absorption of the drug (but not limited to)
Paralysis of intestine and intestinal obstruction
Gastrointestinal surgery that has a clinically significant effect on
absorption of the drug: gastrotomy, small intestinal fistula, extensive small
bowel resection, etc. (except for simple anastomosis)
Autoimmune or inflammatory disease that involves the entire gastrointestinal
system or small intestines: coeliac disease, intestinal graft versus host
disease, Behcet's syndrome, scleroderma involving the gastrointestinal tract
Crohn's disease, ulcerative colitis, etc
) Lung diseases (but not limited to)
New or progressive dyspnea, cough, and fever
Planned diagnosis of interstitial lung disease, or interstitial pneumonia
Pulmonary fibrosis 6) Hematologic malignancy including lymphoma 7) Metastasis
Central nervous system metastasis or brain metastasis Bone metastasis 8) Infectious disease (but not limited to)
Severe infectious disease requiring administration of antibiotics, antivirals, etc. that may affect the safety and efficacy assessments during the study
Active (overt) infectious disease that is uncontrolled by the adequate and optimal treatments as determined by the investigator 9) Known positive human immunodeficiency virus (HIV) 10) Active hepatitis B or active hepatitis C
HBsAg positive with HBV DNA detected Anti-HCV positive with HCV RNA detected (qualitatively) 11) Unintentional weight loss > 10% within 12 weeks prior to informed consent 12) History of alcohol or other drug abuse within 1 year (52 weeks) prior to informed consent
Subjects who received, are receiving, or cannot stop the following therapy
(medication/non-medication) 13) Subjects who need antineoplastic therapy
other than the IP during the study participation (Point radiation to alleviate
bronchial obstruction, skin lesion, etc. is allowed)
Surgery, radio(chemo)therapy, cytotoxic chemotherapy, targeted therapy (small molecule drug, monoclonal antibody), immuno-oncology drug (biological drug), hormone therapy, etc. 14) Subjects who received (used) other investigational study product or device within 2 weeks or 5 half-lives prior to informed consent (whichever is shorter) 15) Subjects on drugs (nonprescription drug, herb, homeopathy, etc.) that have a significant effect on the assessment of kinetics (metabolism, excretion, etc. in the body) or efficacy and safety of the IP within 2 weeks prior to informed consent as determined by the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note